Blog Post


June is Elder Abuse Awareness Month, and the FDA’s approval of a new drug for Alzheimer’s disease provides hope of a possible treatment.  On June 7, 2021, the Food and Drug Administration (FDA) granted accelerated approval of a new drug called Aduhelm for the treatment of Alzheimer’s disease.  Aduhelm is the first new treatment approved for Alzheimer’s since 2003 and is the first Alzheimer’s drug that targets the underlying pathophysiology of Alzheimer’s.  The drug is not yet available but should be shipping around the country over the next few weeks.

Since the announcement, the FDA has received some criticism of its decision to grant Aduhelm accelerated approval, with many arguing the approval was premature.  In addition, three FDA advisors resigned following the decision.  However, the FDA ordered Biogen, the creator of Aduhelm, to conduct an additional study, and the FDA will consider withdrawing its approval of Aduhelm if the study does not verify the drug’s clinical benefit.

Alzheimer’s is an issue near and dear to our hearts here at Lindley Law, and we remain optimistic about the FDA’s approval of Aduhelm and its potential to help those suffering from Alzheimer’s.  Much of our practice is devoted to protecting the elderly and those suffering from all forms of dementia, including Alzheimer’s, from fraud and elder abuse.  We have participated in the Alzheimer’s Association’s Walk to End Alzheimer’s for the past few years, and we are excited to participate once again this October.

This year we are doubling our fundraising goal to $10,000 as COVID prohibited us from participating last year.  Lindley Law would greatly appreciate your support by donating to our fundraising page today!

For more information regarding our firm, attorneys, and practice areas, please visit our website at